echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > 60% of patients' tumors have shrunk significantly, cancer vaccine/Keytruda combination therapy achieves positive results again

    60% of patients' tumors have shrunk significantly, cancer vaccine/Keytruda combination therapy achieves positive results again

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 12, 2021, Ultimovacs announced that its cancer vaccine UV1 combined with anti-PD-1 therapy Keytruda (pembrolizumab) has achieved positive top-line results in the second patient cohort (n=10) in a phase 1 clinical trial


    UV1 targets human telomerase (hTERT)


    In the second patient cohort of the Phase 1 trial, the tumor-killing efficacy of UV1+pembrolizumab combination therapy was similar to that of the first cohort (n=20)


    Reference materials:

    [1] Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.